NZ600544A - Compositions and methods for the treatment of angiogenesis-related eye diseases - Google Patents
Compositions and methods for the treatment of angiogenesis-related eye diseasesInfo
- Publication number
- NZ600544A NZ600544A NZ600544A NZ60054410A NZ600544A NZ 600544 A NZ600544 A NZ 600544A NZ 600544 A NZ600544 A NZ 600544A NZ 60054410 A NZ60054410 A NZ 60054410A NZ 600544 A NZ600544 A NZ 600544A
- Authority
- NZ
- New Zealand
- Prior art keywords
- angiogenesis
- treatment
- seq
- compositions
- methods
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title abstract 2
- 208000030533 eye disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- ZTYNVDHJNRIRLL-FWZKYCSMSA-N rhodostomin Chemical compound C([C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CSSC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(O)=O)[C@@H](C)O)=O)CSSC[C@H]2C(=O)N[C@H]3CSSC[C@@H](C(NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H]2NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)CN)CSSC2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N4)=O)CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N[C@@H](CCCCN)C(=O)N1)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=CC=C1 ZTYNVDHJNRIRLL-FWZKYCSMSA-N 0.000 abstract 4
- 108010049985 rhodostomin Proteins 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28962409P | 2009-12-23 | 2009-12-23 | |
| PCT/US2010/061738 WO2011079175A1 (en) | 2009-12-23 | 2010-12-22 | Compositions and methods for the treatment of angiogenesis-related eye diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ600544A true NZ600544A (en) | 2014-06-27 |
Family
ID=44151942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ600544A NZ600544A (en) | 2009-12-23 | 2010-12-22 | Compositions and methods for the treatment of angiogenesis-related eye diseases |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9044436B2 (https=) |
| EP (1) | EP2515926A4 (https=) |
| JP (1) | JP5739908B2 (https=) |
| KR (1) | KR20120130752A (https=) |
| CN (1) | CN102883738A (https=) |
| AR (1) | AR079706A1 (https=) |
| AU (1) | AU2010336475A1 (https=) |
| BR (1) | BR112012015188A8 (https=) |
| CA (1) | CA2782796A1 (https=) |
| MX (1) | MX2012007416A (https=) |
| NZ (1) | NZ600544A (https=) |
| RU (1) | RU2012131251A (https=) |
| TW (1) | TWI581801B (https=) |
| WO (1) | WO2011079175A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101722961B1 (ko) | 2009-02-11 | 2017-04-04 | 알부메딕스 에이/에스 | 알부민 변이체 및 접합체 |
| US20110015130A1 (en) * | 2009-07-20 | 2011-01-20 | Woei-Jer Chuang | Polypeptides Selective for alphavbeta3 Integrin Conjugated With a Variant Of Human Serum Albumin (HSA) And Pharmaceutical Uses Thereof |
| CA2776241A1 (en) | 2009-10-30 | 2011-05-05 | Novozymes Biopharma Dk A/S | Albumin variants |
| US10233228B2 (en) | 2010-04-09 | 2019-03-19 | Albumedix Ltd | Albumin derivatives and variants |
| EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| WO2013135896A1 (en) | 2012-03-16 | 2013-09-19 | Novozymes Biopharma Dk A/S | Albumin variants |
| MX2015005363A (es) | 2012-11-08 | 2015-11-06 | Novozymes Biopharma Dk As | Variantes de albumina. |
| KR101724129B1 (ko) * | 2014-03-28 | 2017-04-10 | 연세대학교 산학협력단 | Rgd 모티프를 포함하는 펩타이드 또는 단백질을 포함하는 신경염증 예방, 억제 또는 치료용 조성물 |
| US10508137B2 (en) * | 2014-08-22 | 2019-12-17 | National Cheng Kung Univeristy | Disintegrin variants and pharmaceutical uses thereof |
| EP3241557B1 (en) | 2014-12-31 | 2020-09-09 | Huons Co., Ltd. | Composition, containing rgd motif-containing peptide or fragment thereof, for alleviating skin wrinkles |
| ES2797901T3 (es) | 2015-06-28 | 2020-12-04 | Allgenesis Biotherapeutics Inc | Proteínas de fusión para la inhibición de angiogénesis |
| WO2017029407A1 (en) | 2015-08-20 | 2017-02-23 | Albumedix A/S | Albumin variants and conjugates |
| US12304037B2 (en) | 2021-11-03 | 2025-05-20 | Aob Products Company | Torque driver |
| US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
| CN121666229A (zh) | 2023-08-04 | 2026-03-13 | (株)来时协乐 | 包含i型胶原蛋白和色素上皮衍生因子肽作为活性成分的、用于预防或治疗新生血管性眼病的滴眼液组合物 |
| KR20250021281A (ko) | 2023-08-04 | 2025-02-12 | 주식회사 넥스세라 | 콜라겐 타입 i 및 색소 상피성 인자 펩타이드를 유효성분으로 포함하는 안구 혈관신생 질환의 예방 또는 치료용 점안제 조성물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US6710030B1 (en) | 1993-10-22 | 2004-03-23 | University Of Southern California | Contortrostain (CN) and methods for its use in preventing metastasis and other conditions |
| US5659018A (en) * | 1995-08-01 | 1997-08-19 | Genetics Institute, Inc. | Mocarhagin, a cobra venom protease, and therapeutic uses thereof |
| WO2003042354A2 (en) * | 2001-09-04 | 2003-05-22 | Aventis Pharmaceuticals Inc. | Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis |
| CA2489186C (en) | 2002-06-07 | 2013-01-15 | Wisconsin Alumni Research Foundation | Chemical synthesis of reagents for peptide coupling |
| WO2006119128A2 (en) * | 2005-04-29 | 2006-11-09 | Research Development Foundation | Vascular targeting of ocular neovascularization |
| US7943728B2 (en) * | 2006-12-26 | 2011-05-17 | National Cheng Kung University | Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases |
| US20110015130A1 (en) * | 2009-07-20 | 2011-01-20 | Woei-Jer Chuang | Polypeptides Selective for alphavbeta3 Integrin Conjugated With a Variant Of Human Serum Albumin (HSA) And Pharmaceutical Uses Thereof |
-
2010
- 2010-12-22 US US12/975,630 patent/US9044436B2/en not_active Expired - Fee Related
- 2010-12-22 EP EP20100840104 patent/EP2515926A4/en not_active Withdrawn
- 2010-12-22 CN CN2010800594090A patent/CN102883738A/zh active Pending
- 2010-12-22 BR BR112012015188A patent/BR112012015188A8/pt not_active IP Right Cessation
- 2010-12-22 AR ARP100104891A patent/AR079706A1/es unknown
- 2010-12-22 JP JP2012546185A patent/JP5739908B2/ja not_active Expired - Fee Related
- 2010-12-22 WO PCT/US2010/061738 patent/WO2011079175A1/en not_active Ceased
- 2010-12-22 CA CA2782796A patent/CA2782796A1/en not_active Abandoned
- 2010-12-22 KR KR1020127019529A patent/KR20120130752A/ko not_active Withdrawn
- 2010-12-22 NZ NZ600544A patent/NZ600544A/en not_active IP Right Cessation
- 2010-12-22 MX MX2012007416A patent/MX2012007416A/es not_active Application Discontinuation
- 2010-12-22 RU RU2012131251/15A patent/RU2012131251A/ru not_active Application Discontinuation
- 2010-12-22 AU AU2010336475A patent/AU2010336475A1/en not_active Abandoned
- 2010-12-23 TW TW099145616A patent/TWI581801B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012007416A (es) | 2012-07-23 |
| CA2782796A1 (en) | 2011-06-30 |
| AU2010336475A1 (en) | 2012-06-14 |
| KR20120130752A (ko) | 2012-12-03 |
| AR079706A1 (es) | 2012-02-15 |
| EP2515926A1 (en) | 2012-10-31 |
| US9044436B2 (en) | 2015-06-02 |
| JP5739908B2 (ja) | 2015-06-24 |
| CN102883738A (zh) | 2013-01-16 |
| WO2011079175A1 (en) | 2011-06-30 |
| BR112012015188A2 (pt) | 2016-04-05 |
| RU2012131251A (ru) | 2014-01-27 |
| US20110152192A1 (en) | 2011-06-23 |
| TW201138801A (en) | 2011-11-16 |
| JP2013515739A (ja) | 2013-05-09 |
| TWI581801B (zh) | 2017-05-11 |
| EP2515926A4 (en) | 2013-10-09 |
| BR112012015188A8 (pt) | 2016-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ600544A (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| AU2018201997B2 (en) | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| RU2012140704A (ru) | Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция | |
| NZ589445A (en) | Rasagiline for parkinson's disease modification | |
| JP2013520405A5 (https=) | ||
| NZ611628A (en) | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients | |
| SG150531A1 (en) | Use of meloxicam for the treatment of respiratory diseases in pigs | |
| EA201270041A1 (ru) | Лечение рассеянного склероза лаквинимодом | |
| NZ602510A (en) | Treatment of lupus nephritis using laquinimod | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| BR112015010396A2 (pt) | terapia de combinação | |
| WO2012007159A3 (en) | Novel gastro-retentive dosage forms | |
| MX2009004561A (es) | Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor. | |
| JP2011225596A5 (https=) | ||
| NZ600583A (en) | Visfatin therapeutic agents for the treatment of acne and other conditions | |
| MX2009012922A (es) | Vacunacion intradermica de un peptido del virus del papiloma humano. | |
| EA201171087A1 (ru) | СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ | |
| MX350195B (es) | Analogos de cistamina para el tratamiento de la enfermedad de parkinson. | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 DEC 2015 BY BALDWINS INTELLECTUAL PROPERTY Effective date: 20150130 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 DEC 2016 BY CPA GLOBAL Effective date: 20151222 |
|
| LAPS | Patent lapsed |